News for Oncolytics Biotech Inc. (ONCY)

PR NewswireVANCOUVER, BC, May 23, 2025 Equity Insider News CommentaryIssued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, May 23, 2025 /PRNewswire/ --

PR NewswireSAN DIEGO and CALGARY, AB, May 23, 2025 Pelareorep initiates a pro-inflammatory tumor microenvironment (TME) and induces innate and adaptive imm

Oncolytics Biotech (ONCY) revealed promising findings from its Phase I/II GOBLET clinical trial at the 2025 American Society of Clinical Oncology Annual Meeting

On May 21, 2025, HC Wainwright & Co. maintained its "Buy" rating for Oncolytics Biotech (ONCY). In the latest report, analyst Patrick Trucchio reiterated the st

Operator: Good afternoon, and welcome to Oncolytics Biotech First Quarter Conference Call. All participants are in a listen-only mode.

Cash and Cash Equivalents: $15.3 million as of March 31, 2025.Net Cash Operating Activities: $6.5 million for the quarter, down from $7.5 million in the same p

May 14, 2025 / 08:30PM GMTOperator Good afternoon and welcome to Oncolytics Biotech's first-quarter conference call. (Operator Instructions) Please be advised t

PR NewswireSAN DIEGO and CALGARY, AB, May 6, 2025 Conference call and webcast to take place on Wednesday, May 14, 2025, at 4:30 p.m. ET

Oncolytics Biotech (ONCY) will host its Q1 2025 earnings call on May 14, 2025, at 4:30 p.m. ET. The call will cover financial results and a corporate up

PR NewswireVANCOUVER, BC, May 1, 2025 Equity Insider News CommentaryIssued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, May 1, 2025 /PRNewswire/ -- E

PR NewswireSAN DIEGO and CALGARY, AB, April 24, 2025 ASCO data expected to highlight how pelareorep activates immune responses in pancreatic cancer patient

Oncolytics Biotech (ONCY) to present new pancreatic cancer data at ASCO 2025 in Chicago. Pelareorep demonstrates encouraging anti-tumor activity in panc

PR NewswireVANCOUVER, BC, April 14, 2025 Equity Insider News CommentaryIssued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, April 14, 2025 /PRNewswire

PR NewswireSAN DIEGO and CALGARY, AB, April 10, 2025 SAN DIEGO and CALGARY, AB, April 10, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TS

Oncolytics Biotech (ONCY) secures up to US$20 million funding through a share purchase agreement with Alumni Capital LP. Oncolytics maintains control ov

PR NewswireSAN DIEGO and CALGARY, AB, April 10, 2025 SAN DIEGO and CALGARY, AB, April 10, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TS

Oncolytics Biotech Inc. (NASDAQ: ONCY) discussed at H.C. Wainwright event for oncolytic immunotherapies in breast and pancreatic cancers. Experts highlighte

Oncolytics Biotech faces financial struggles and unclear pelareorep efficacy signals. Learn why ONCY stock's risks outweigh potential rewards.

PR NewswireVANCOUVER, BC, March 8, 2025 USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, March 8, 2025 /PRNewswire/